Published online Jun 27, 2021. doi: 10.4240/wjgs.v13.i6.574
Peer-review started: January 10, 2021
First decision: February 14, 2021
Revised: February 26, 2021
Accepted: June 1, 2021
Article in press: June 1, 2021
Published online: June 27, 2021
Processing time: 158 Days and 20.4 Hours
There is increasing literature connecting acute pancreatitis (AP) and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, but whether SARS-CoV-2 can cause AP or is an epiphenomenon remains a subject of debate.
To explore current literature and provide a concise overview of the current evidence as well as possible mechanisms of pancreatic injury in coronavirus disease 2019 (COVID-19) patients.
To provide an overview of current evidence on AP in COVID-19 patients and to promote and enhance future studies on this special subset of patients.
Systematic and narrative review of the literature.
Available studies on AP in COVID-19 patients present important limitations and mechanisms of pancreatic injury are debatable and not completely understood.
Currently there is insufficient evidence showing that SARS-CoV-2 infection can cause AP and the therapeutic and prognostic significance of AP in COVID-19 patients is largely unknown.
This is a very important issue, requiring ongoing research.
